vs
Side-by-side financial comparison of Incyte (INCY) and KEMPER Corp (KMPR). Click either name above to swap in a different company.
Incyte is the larger business by last-quarter revenue ($1.3B vs $1.1B, roughly 1.1× KEMPER Corp). Incyte runs the higher net margin — 23.8% vs -0.7%, a 24.5% gap on every dollar of revenue. On growth, Incyte posted the faster year-over-year revenue change (20.9% vs -4.7%). Over the past eight quarters, Incyte's revenue compounded faster (10.4% CAGR vs -0.5%).
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Kemper Corporation is an American insurance provider with corporate headquarters located in Chicago, Illinois. With nearly $13 billion in assets, the Kemper family of companies provides insurance to individuals, families, and businesses.
INCY vs KMPR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $1.1B |
| Net Profit | $303.3M | $-8.0M |
| Gross Margin | — | — |
| Operating Margin | 23.7% | — |
| Net Margin | 23.8% | -0.7% |
| Revenue YoY | 20.9% | -4.7% |
| Net Profit YoY | 91.7% | -108.2% |
| EPS (diluted) | $1.47 | $-0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.5B | $1.1B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.1B | $1.2B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.1B | $1.2B | ||
| Q2 24 | $1.0B | $1.1B |
| Q1 26 | $303.3M | — | ||
| Q4 25 | $299.3M | $-8.0M | ||
| Q3 25 | $424.2M | $-21.0M | ||
| Q2 25 | $405.0M | $72.6M | ||
| Q1 25 | $158.2M | $99.7M | ||
| Q4 24 | $201.2M | $97.4M | ||
| Q3 24 | $106.5M | $73.7M | ||
| Q2 24 | $-444.6M | $75.4M |
| Q1 26 | — | — | ||
| Q4 25 | 92.0% | — | ||
| Q3 25 | 92.8% | — | ||
| Q2 25 | 93.5% | — | ||
| Q1 25 | 93.0% | — | ||
| Q4 24 | 92.5% | — | ||
| Q3 24 | 92.4% | — | ||
| Q2 24 | 92.7% | — |
| Q1 26 | 23.7% | — | ||
| Q4 25 | 22.3% | — | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 43.6% | — | ||
| Q1 25 | 19.5% | — | ||
| Q4 24 | 25.6% | — | ||
| Q3 24 | 12.8% | 11.2% | ||
| Q2 24 | -45.8% | 10.1% |
| Q1 26 | 23.8% | — | ||
| Q4 25 | 19.9% | -0.7% | ||
| Q3 25 | 31.1% | -1.7% | ||
| Q2 25 | 33.3% | 5.9% | ||
| Q1 25 | 15.0% | 8.4% | ||
| Q4 24 | 17.1% | 8.2% | ||
| Q3 24 | 9.4% | 6.3% | ||
| Q2 24 | -42.6% | 6.7% |
| Q1 26 | $1.47 | — | ||
| Q4 25 | $1.46 | $-0.03 | ||
| Q3 25 | $2.11 | $-0.34 | ||
| Q2 25 | $2.04 | $1.12 | ||
| Q1 25 | $0.80 | $1.54 | ||
| Q4 24 | $0.90 | $1.51 | ||
| Q3 24 | $0.54 | $1.14 | ||
| Q2 24 | $-2.04 | $1.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | $943.5M |
| Stockholders' EquityBook value | $5.6B | $2.7B |
| Total Assets | $7.3B | $12.5B |
| Debt / EquityLower = less leverage | — | 0.35× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | — | ||
| Q3 25 | $2.5B | $371.2M | ||
| Q2 25 | $2.0B | $407.6M | ||
| Q1 25 | $1.9B | $545.3M | ||
| Q4 24 | $1.7B | $1.0B | ||
| Q3 24 | $1.3B | $696.9M | ||
| Q2 24 | $987.3M | $539.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | $943.5M | ||
| Q3 25 | — | $943.1M | ||
| Q2 25 | — | $942.6M | ||
| Q1 25 | — | $942.1M | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B |
| Q1 26 | $5.6B | — | ||
| Q4 25 | $5.2B | $2.7B | ||
| Q3 25 | $4.7B | $2.7B | ||
| Q2 25 | $4.2B | $370.0M | ||
| Q1 25 | $3.7B | $366.0M | ||
| Q4 24 | $3.4B | $2.8B | ||
| Q3 24 | $3.2B | $2.8B | ||
| Q2 24 | $3.0B | $358.0M |
| Q1 26 | $7.3B | — | ||
| Q4 25 | $7.0B | $12.5B | ||
| Q3 25 | $6.3B | $12.4B | ||
| Q2 25 | $5.8B | $12.6B | ||
| Q1 25 | $5.7B | $12.5B | ||
| Q4 24 | $5.4B | $12.6B | ||
| Q3 24 | $5.0B | $12.6B | ||
| Q2 24 | $4.7B | $12.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 2.55× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | — | 0.50× | ||
| Q3 24 | — | 0.50× | ||
| Q2 24 | — | 3.88× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $175.0M |
| Free Cash FlowOCF − Capex | — | $166.2M |
| FCF MarginFCF / Revenue | — | 14.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $553.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $543.3M | $175.0M | ||
| Q3 25 | $559.4M | $139.9M | ||
| Q2 25 | $44.7M | $89.6M | ||
| Q1 25 | $266.1M | $180.0M | ||
| Q4 24 | $381.2M | $175.1M | ||
| Q3 24 | $310.9M | $141.9M | ||
| Q2 24 | $-575.6M | $22.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $166.2M | ||
| Q3 25 | — | $133.4M | ||
| Q2 25 | — | $82.0M | ||
| Q1 25 | — | $172.3M | ||
| Q4 24 | — | $165.4M | ||
| Q3 24 | — | $131.4M | ||
| Q2 24 | — | $5.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | 14.7% | ||
| Q3 25 | — | 10.8% | ||
| Q2 25 | — | 6.7% | ||
| Q1 25 | — | 14.4% | ||
| Q4 24 | — | 13.9% | ||
| Q3 24 | — | 11.1% | ||
| Q2 24 | — | 0.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.82× | — | ||
| Q3 25 | 1.32× | — | ||
| Q2 25 | 0.11× | 1.23× | ||
| Q1 25 | 1.68× | 1.81× | ||
| Q4 24 | 1.89× | 1.80× | ||
| Q3 24 | 2.92× | 1.93× | ||
| Q2 24 | — | 0.30× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INCY
Segment breakdown not available.
KMPR
| Specialty Property Casualty Insurance Segment | $995.1M | 88% |
| Life Insurance Segment1 | $140.7M | 12% |
